

1 **Epidemiological profile, trend, seasonality, and factors**  
2 **associated with Yellow fever disease and barriers to**  
3 **vaccination: a retrospective observational study of multi-**  
4 **season national surveillance data in Nigeria, 2017 - 2021.**

5 Stephen Eghelakpo Akar<sup>1,2,3</sup>, William Nwachukwu<sup>3</sup>, Sunbo Oludare Adewuyi<sup>1</sup>, Anthony  
6 Agbakizua Ahumibe<sup>1,2</sup>, Iniobong Akanimo<sup>3</sup>, Oyeladun Okunromade<sup>3</sup>, Chinwe Ochu<sup>3</sup>, Olajumoke  
7 Babatunde<sup>3</sup>, Ifedayo Adetifa<sup>3</sup>, Chikwe Ihekweazu<sup>4</sup>, Mami Hitachi<sup>2</sup>, Kentaro Kato<sup>2</sup>, Yuki  
8 Takamatsu<sup>5</sup>, Kenji Hirayama<sup>6</sup>, Satoshi Kaneko<sup>2\*</sup>

9 <sup>1</sup>Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

10 <sup>2</sup>Department of Eco-epidemiology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

11 <sup>3</sup>Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria

12 <sup>4</sup>WHO Hub for Pandemic and Epidemic Intelligence, Berlin, Germany

13 <sup>5</sup>Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

14 <sup>6</sup>School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

15 **\*Corresponding author**

16 **[Email: skaneko@nagasaki-u.ac.jp](mailto:skaneko@nagasaki-u.ac.jp)** (SK)

17

18

19

20

## 21 **Abstract**

22 Since its resurgence in 2017, Yellow fever (YF) outbreaks have continued to occur in Nigeria  
23 despite routine immunization and implementation of several reactive mass vaccination campaigns,  
24 resulting in substantial morbidity and mortality. Nigeria is considered a high-priority country for  
25 implementing the WHO EYE strategy, which is targeted at eliminating YF outbreaks by 2026.  
26 This retrospective observational study was conducted to describe the epidemiological profile of  
27 reported cases, trends, and seasonality of YF incidence; identify factors associated with Yellow  
28 fever disease (YFD) and barriers to YF vaccination in Nigeria. Univariate, bivariate and  
29 multivariate binary logistic regression analysis was done. Of 13014 suspected YF cases, 7640  
30 (58.7%) had laboratory confirmation for Yellow fever virus (YFV). Predictors of YFD were male  
31 sex (aOR 2.36, 95% CI: 1.45-3.91) compared to female; age group being 15-29 years (aOR 4.13,  
32 95% CI: 1.59-13.00) compared to under-five; residing in the Derived Savannah (aOR 30.10, 95%  
33 CI: 11.50-104.00), Lowland/Mangrove/Freshwater rainforest (aOR 8.84, 95% CI: 3.24-31.10),  
34 Guinea Savannah/Jos Plateau (aOR 6.13, 95% CI: 1.90-23.50) compared to the Sahel/Sudan  
35 savannah; working in outdoor settings compared to indoor (aOR 1.76, 95% CI: 0.96-3.22); and  
36 vomiting (aOR 2.62, 95% CI: 1.39-4.83). The rainy season was protective against YFD (aOR 0.32,  
37 95% CI: 0.19-0.52) compared to the dry season. Because being unvaccinated emerged as  
38 protective factor (aOR:0.51, 95% CI: 0.25-1.00) compared to those with unknown vaccination  
39 status, the data was further disaggregated by vaccination status. Predictors with higher odds ratios  
40 were found among unvaccinated. Predictors of YFD among the vaccinated were the first quarter  
41 compared to the second quarter of the year (aOR 4.04, 95% CI: 1.48-12.95) and residing in the  
42 southern region compared to the north (aOR 14.03, 95% CI: 4.09-88.27). Barriers to YF  
43 vaccination were the rainy season compared to the dry season (aOR 1.29, 95% CI: 1.05-1.57),

44 being 15 years or older (15-29: aOR 2.06, 95% CI: 1.51-2.83; 30-44: aOR 2.11, 95% CI: 1.45-  
45 3.07; 45-59: aOR 2.72, 95% CI: 1.63-4.58; 60+: aOR 6.55, 95% CI: 2.76-17.50), residing in the  
46 northern region (aOR 3.71, 95% CI: 3.01-4.58) compared to the south, and occupation being  
47 butcher/hunter/farmer (aOR 2.30, 95% CI: 1.52-3.50) compared to home-based/office workers.  
48 Being a student was protective against being unvaccinated (aOR 0.62, 95% CI: 0.47-0.83). Several  
49 factors were associated with YFD, which were aggravated by lack of vaccination. Although  
50 barriers to vaccination were elucidated, inadequate vaccination coverage alone may not account  
51 for the recurrent outbreaks of YF in Nigeria. These findings are critical for planning public health  
52 interventions and to guide further research that would enable Nigeria end YF epidemics.

## 53 **Introduction**

54 Yellow fever (YF), an arthropod-borne, re-emerging viral hemorrhagic illness, caused by the  
55 Yellow fever virus (YFV), has remained a significant public health concern in Africa and the  
56 Americas, accounting for about 29,000 to 60,000 deaths annually [1-8]. An effective and safe  
57 vaccine against YFV, the live attenuated YF 17D vaccine, has been available for over seventy  
58 years and integrated into routine immunization (RI) program in endemic countries. The vaccine  
59 has been shown to confer 95% protection in vaccinated populations within 30 days of vaccine  
60 uptake and offers life-long immunity [5,6,9-13]. Infected persons present with a broad spectrum of  
61 clinical disease, ranging from asymptomatic infections and mild febrile illness to severe disease  
62 and death. It is estimated that 15-25% of infected symptomatic persons progress to severe disease  
63 with a case fatality rate of 20-60% [6,14].

64 Despite the existence of RI for YF and the implementation of several mass preventative and  
65 reactive vaccination campaigns, YF outbreaks have continued to occur in Nigeria since its  
66 resurgence in 2017. Previous studies in Nigeria have focused on the descriptive epidemiology of

67 outbreak cases [6,11] and vaccination program implementation [5,15]. Tobin *et al.* (2021) assessed  
68 the knowledge and attitudes towards YF in a cross-sectional study conducted in a small community  
69 in one of the hotspots states in southern Nigeria [16]. There is paucity of studies on the factors  
70 associated with YFD and YF vaccination in Nigeria. The trend and seasonality of YF in Nigeria  
71 has not also been adequately described.

72 The Eliminate Yellow fever Epidemics (EYE) strategy of the World Health Organization is  
73 targeted at eliminating YF outbreaks in endemic countries by the year 2026, and Nigeria is  
74 considered a high priority country for its implementation [17]. The EYE strategy is aimed at  
75 protecting at-risk population, preventing international spread of YF, and containing local outbreaks  
76 of YF promptly [17]. The objective of this study is to describe the epidemiological profile of  
77 reported YF cases, trends, and seasonality of YF incidence; as well as identify factors associated  
78 with YFD and barriers to YF vaccination in Nigeria. This has become imperative as public health  
79 authorities aim to develop strategic public health interventions to enable the country to meet the  
80 2026 target of the WHO EYE strategy.

## 81 **Methods**

### 82 **Data Source Description**

83 We retrospectively analyzed YF surveillance data obtained from the Surveillance, Outbreak,  
84 Response, Management, and Analysis System (SORMAS) platform managed by the Nigeria  
85 Centre for Disease Control (NCDC) to which State ministries and Local Government departments  
86 of health reported. SORMAS in Nigeria, part of the integrated disease surveillance and response  
87 system (IDSR), has been previously described [5,11]. In brief, once a patient meets the standard  
88 case definition for a suspected case of YF, the attending physician notifies the Local Government  
89 Area (LGA) Disease Surveillance and Notification Officer (DSNO); the LGA DSNO then notifies

90 the State Epidemiologist and the State DSNO, who verifies the case and then inform the focal  
91 person at the NCDC. The NCDC, in conjunction with the State and the LGA officers, constitutes  
92 an outbreak investigation team to investigate the case using a case investigation form (CIF). The  
93 cases are line-listed, and blood samples are collected for laboratory confirmation in line with the  
94 National Guidelines for YF Preparedness and Response [5,18]. Serological testing involved the  
95 detection of YF-specific antibodies in the serum samples of suspected cases using Enzyme-linked  
96 Immunosorbent Assay (ELISA; U.S. CDC MAC protocol; done in-country) and plaque reduction  
97 neutralization test (PRNT; done at the Regional Reference Laboratory, Dakar, Senegal). ELISA  
98 positive results were recorded as “presumptive positive” while negative results were recorded as  
99 “negative cases”. Both ELISA positive samples and “inconclusive samples” were sent to the  
100 Regional Reference Laboratory for confirmation by PRNT. Molecular testing by real-time  
101 polymerase chain reaction (RT-PCR) was done in-country for samples collected from suspected  
102 cases within ten days of onset of symptoms to detect YF viral genome in blood. PCR negative  
103 samples were further tested by serology to rule out false negative results while positive samples  
104 are reported as confirmed YF cases [18]. Information on the CIF is logged into the SORMAS  
105 platform using the epidemiological number issued by the State Epidemiologist as a unique  
106 identifier. The data abstracted from the SORMAS platform include epidemiological number,  
107 socio-demographic information (age, sex, education, occupation), vaccination status, clinical  
108 information (date of onset, date of admission, symptoms), location (state), travel history, and  
109 laboratory test status (negative, positive, unconfirmed) from July 2017 to December 2021.

## 110 **Case definition**

111 The case definitions applied for YF surveillance in Nigeria are as follows: A suspected case of YF  
112 was defined as “any person with acute onset of fever or history of fever and/or general body

113 weakness, vomiting, bleeding from any part of the body, and jaundice appearing within 14 days  
114 of onset of the first symptom” [18]. A presumptive case was defined as a “suspected case in whom  
115 was found the presence of YF IgM antibody in the absence of YF vaccination within the last 30  
116 days before onset of illness or positive post-mortem liver histopathology or epidemiological link  
117 to a confirmed case or an outbreak”. A confirmed case was defined as “ presumptive case with one  
118 of the following: detection of YF IgM; detection of four-fold rise in IgM or IgG antibody titers  
119 between acute and convalescent serum samples or both; detection of YF-specific neutralizing  
120 antibodies and absence of YF immunization within 30 days before onset of illness or one of the  
121 following: detection of YF viral genome in blood, liver or other organs by immunoassay, isolation  
122 of YF virus and absence of YF immunization within 14 days before onset of illness [18]. However,  
123 for this study, a positive case was defined as a suspected case that was confirmed positive for YFV  
124 by either serology or RT-PCR. A negative case is a suspected case that was confirmed negative by  
125 both serology and RT-PCR. An unconfirmed case is a suspected case for which laboratory test  
126 result was missing in the line list.

## 127 **Additional data sources for the analysis**

128 Administratively, Nigeria has 774 LGAs, which are clustered into 36 states and the Federal Capital  
129 Territory and zoned into six geo-political zones (North-Central, North-East, North-West, South-  
130 East, South-West, and South-South). The geo-political zones were created based on political and  
131 socio-cultural considerations from the northern and southern regions. There are two climatic  
132 seasons in Nigeria (dry season and rainy season). The rainy season begins in April and ends in  
133 October while the dry season commences from November and terminates at about the end of  
134 March [19]. Forests spanned over nine ecological zones [20] (**S1 Fig**). The northern part of the  
135 country is dotted with Savannah-type vegetation whereas the southern region is characterized by

136 weather conditions that promote luxuriant rainforest and proliferation of insect populations. It is  
137 estimated that forest reserves occupy 10% of the total land mass, with 78.7% in the Savannah zone,  
138 7.7% in the derived Savannah zone, and 13.6% in the rain forest zone [19,21]. The ecological  
139 zones have been described as running from the northern to the southern parts in a contiguous  
140 fashion, in which natural ranges extending from the mangrove swamps and tropical forests in the  
141 coastal flanks become shrubs and Savannah woodlands in the low Plateau, which extends into the  
142 semi-arid plains of the northern region in central Nigeria and the eastern highlands. This complex  
143 mesh of forest pattern had resulted in a variety of vegetation in the landscape, including Sahel,  
144 Guinea, and derived Savannah as well as lowland rain forest, freshwater and mangrove forests,  
145 coastal marshes, and estuaries. The ecological zones are repositories of a wide variety of plants  
146 and animal species, including 20,000 insect and 247 mammalian species [19]. The variables geo-  
147 political zone, geographical region, and ecological zone were generated based on the states in  
148 which cases were reported.

## 149 **Definition of variables**

150 Time-oriented variables such as annual quarter, epidemic period (pre-pandemic, pandemic) and  
151 climatic season (dry season, rainy season) were generated by grouping cases by date of onset of  
152 illness. Epidemic period was defined as whether a case developed symptoms before (pre-  
153 pandemic) or during (pandemic) the period of the COVID-19 pandemic (January 2020 and  
154 beyond) while climatic season was defined as whether the case occurred during the months of the  
155 dry season or the rainy season. Socio-demographic factors presumed to be associated with outcome  
156 variables were identified from previous studies [2,4,22]. Age in years and sex were analyzed as  
157 reported by cases and relatives. Age was used to create two sets of age group variables: For the  
158 analysis of factors associated with outcome variables (YFD and being unvaccinated) without

159 disaggregation, age was categorized into seven levels (0-4, 5-9, 10-14, 15-29, 30-44, 45-59, and  
160 60+ years); however, when YFD was disaggregated by vaccination status, age was categorized  
161 into two levels (<15 and >=15 years) to accommodate small sample sizes. Geo-political zone,  
162 geographical region, and ecological zone were generated using the state in which cases were  
163 detected. Educational status was created from the educational level reported by cases – primary,  
164 secondary, tertiary, Islamic education, no education. These were collapsed into two levels: all those  
165 who had any formal education were defined as “educated” and those with no education were  
166 defined as “no education” alongside those who did not report their educational status, considering  
167 the current illiteracy level of nearly 40.0% in Nigeria. Occupational group was generated from the  
168 occupation reported by cases, which were loosely defined. Those working in office settings,  
169 housewives, and kids below school age were grouped as “home-based/office workers”; those who  
170 reported business, trading, plumbing, electrician etc. were grouped as “artisans/traders”. In Nigeria  
171 the term “business” loosely includes people involved in any form of buying and selling of goods  
172 and services. Cases who were of school age (6-17 years) but were not reported as students were  
173 grouped as “students” alongside those who reported being students based on the premise that basic  
174 education is mandatory by law in Nigeria. Those involved in animal sales, butchers, hunters, and  
175 farmers were grouped as “butchers/farmers/hunters”; and those working in healthcare settings  
176 were defined as health workers. Cases who reported no occupation were defined as unemployed  
177 in view of the high unemployment rate in Nigeria.

## 178 **Statistical analysis**

179 De-identified and anonymized national line-list of YF outbreak cases from 1st July 2017 to 31<sup>st</sup>  
180 December 2021 was abstracted from the SORMAS platform in compliance with NCDC data  
181 sharing protocol. We received the dataset in Microsoft Excel format from the data management on



182 5<sup>th</sup> February 2022 with personal identifiers of the cases removed. Categorical variables were  
183 summarized using frequencies and percentages while numerical variables were summarized using  
184 median and inter-quartile range. Our main outcome variables were: (1) YFD, defined as a  
185 suspected case of YF confirmed for YFV by either serology or RT-PCR (a categorical variable  
186 with two levels: No = No YFD, Yes = YFD) and (2) unvaccinated, defined as a suspected with no  
187 previous YF vaccination before the onset of symptoms (a categorical variable with two levels:  
188 No/Yes). Comparison of percentages between outcome and explanatory variables was done using  
189 Pearson's Chi square statistic and Fisher's exact test for categorical variables and Kruskal-Wallis  
190 rank sum test for numerical variables with p-value <0.05 considered to be statistically significant.  
191 We used date of onset of illness to plot epidemic curves with trend lines (histogram with line plots)  
192 and time series seasonality plots (line plot in which cases were aggregated by months over the  
193 entire study period) to show trends of cases over time. A population-adjusted age-sex pyramid of  
194 cases was also plotted using the ages of cases and country age-sex population structure.

195 At bivariate analysis, odds ratio (OR) was used as a measure of association between seasonal,  
196 geographical, socio-demographic, and clinical characteristics and respective outcome variables  
197 (YFD: No = 0, Yes = 1; unvaccinated: No = 0; Yes = 1) and the 95% confidence intervals with p-  
198 values (<0.05) were estimated. Subsequently, multivariate logistic regression analysis was done  
199 using stepwise selection process, which was based on Akaike Information Criterion (AIC) [23] -  
200 implemented in R using the *stepAIC* function in the MASS package [24] with backward selection.

201 Here, explanatory variables with level of significance  $p < 0.15$  at bivariate analysis were included  
202 in the multivariate logistic regression model to determine adjusted odds ratios, 95% confidence  
203 interval, and p-values of predictors of the respective outcomes. We used variance inflation factor  
204 to assess multicollinearity of the variables in the final model and variables that exhibited

205 collinearity values  $\geq 5.0$  were excluded from the final model. For variables that exhibited  
206 collinearity, the one with a higher variance inflation factor was dropped from the final model. For  
207 both outcome variables, bivariate and multivariate analysis was first done with the whole dataset  
208 and then disaggregated by vaccination status (YFD) and laboratory test result (being  
209 unvaccinated). We conducted our analysis with RStudio version 4.4.2 and R version 4.4.2  
210 (<http://posit.co/download/rstudio-desktop/>). The main R packages used in our analysis were the  
211 tidyverse package (data wrangling) [25], tableone package (descriptive table) [26], gtsummary and  
212 finalfit packages (bivariate and multivariate analysis)[27] , and TSstudio package (seasonality  
213 analysis)[28] .

## 214 **Ethical consideration**

215 Approval for this study was sought by submission of the study proposal (see Other supporting  
216 material) to the Research Ethics Committee of the Nigeria Centre for Disease Control and  
217 Prevention, which was reviewed and approved. The Research Ethics Committee then requested  
218 the authors to complete, sign, and submit a data sharing agreement form to access the dataset (see  
219 Other supporting material). The data has been previously collected, stored, and analyzed as part of  
220 outbreak response activity by the NCDC during which a case investigation form was administered  
221 by trained clinical staff to obtain relevant information from suspected cases of YF to which they  
222 consented in writing following detailed explanation about the use of their information by  
223 appending their signature and witnessed by an attending nurse and a family relative. In the case of  
224 minors, informed consent was given by either a parent or guardian. The data was confidentially  
225 stored in passworded computer systems by NCDC data management team and was shared in de-  
226 identified and anonymized Microsoft Excel format for this study. This necessitated a waiver of the  
227 need for informed consent for this study by the Research Ethics Committee.

## 228 Results

### 229 Trend and seasonality of case incidence

230 Case reporting was higher during the 2019 epidemic season (34.0%) while YFV positive case was  
 231 higher during the 2020 epidemic season (44.0%). While suspected case reporting was higher  
 232 during the third and fourth quarter of the year, YFV positivity was more in the fourth quarter of  
 233 the year (Table 1).

234 **Table 1. Seasonal, geographical, and socio-demographic characteristics of YF cases in Nigeria, 2017**  
 235 **and 2021 compared by laboratory test status.**

Variable	Category	Overall	Unconfirmed	YFV Negative	YFV Positive	p-value
No.		13014	5374	7104	536	
		n (%)	n (%)	n (%)	n (%)	
<b>Epidemic season</b>	2017	1229 (9.4)	428 (8.0)	778 (11.0)	23 (4.3)	<b>&lt;0.001</b>
	2018	1922 (14.8)	1154 (21.5)	760 (10.7)	8 (1.5)	
	2019	4430 (34.0)	1828 (34.0)	2392 (33.7)	210 (39.2)	
	2020	3552 (27.3)	1228 (22.9)	2088 (29.4)	236 (44.0)	
	2021	1881 (14.5)	736 (13.7)	1086 (15.3)	59 (11.0)	
<b>Annual quarter</b>	First quarter	3001 (23.1)	710 (13.2)	2198 (30.9)	93 (17.4)	<b>&lt;0.001</b>
	Second quarter	2425 (18.6)	813 (15.1)	1593 (22.4)	19 (3.5)	
	Third quarter	3774 (29.0)	1806 (33.6)	1834 (25.8)	134 (25.0)	
	Fourth quarter	3814 (29.3)	2045 (38.1)	1479 (20.8)	290 (54.1)	
<b>Epidemic period</b>	Pandemic	5433 (41.7)	1964 (36.5)	3174 (44.7)	295 (55.0)	<b>&lt;0.001</b>
	Pre-pandemic	7581 (58.3)	3410 (63.5)	3930 (55.3)	241 (45.0)	
<b>Climatic season</b>	Dry season	5423 (41.7)	1964 (36.5)	3152 (44.4)	307 (57.3)	<b>&lt;0.001</b>
	Rainy season	7591 (58.3)	3410 (63.5)	3952 (55.6)	229 (42.7)	
<b>Geo-political zone</b>	North-central	1892 (14.5)	703 (13.1)	1110 (15.6)	79 (14.7)	<b>&lt;0.001</b>
	North-east	1896 (14.6)	826 (15.4)	946 (13.3)	124 (23.1)	
	North-west	3727 (28.6)	1892 (35.2)	1793 (25.2)	42 (7.8)	
	South-east	2622 (20.1)	1142 (21.3)	1335 (18.8)	145 (27.1)	
	South-south	1689 (13.0)	585 (10.9)	997 (14.0)	107 (20.0)	
	South-west	1188 (9.1)	226 (4.2)	923 (13.0)	39 (7.3)	
<b>Ecological zone</b>	Derived savannah	3431 (26.4)	1398 (26.0)	1825 (25.7)	208 (38.8)	<b>&lt;0.001</b>
	Freshwater/mangrove/coastal forest	999 (7.7)	297 (5.5)	626 (8.8)	76 (14.2)	
	Guinea savannah	949 (7.3)	356 (6.6)	579 (8.2)	14 (2.6)	
	Jos plateau	1033 (7.9)	427 (7.9)	492 (6.9)	114 (21.3)	
	Lowland rainforest	1836 (14.1)	552 (10.3)	1222 (17.2)	62 (11.6)	
	Sahel savannah	1095 (8.4)	548 (10.2)	536 (7.5)	11 (2.1)	
	Sudan savannah	3671 (28.2)	1796 (33.4)	1824 (25.7)	51 (9.5)	
<b>Sex</b>	Female	5658 (43.5)	2253 (41.9)	3210 (45.2)	195 (36.4)	<b>&lt;0.001</b>
	Male	7356 (56.5)	3121 (58.1)	3894 (54.8)	341 (63.6)	
<b>Age [median {IQR}] years</b>		18.0 [7.0, 30.0]	18.0 [7.0, 30.0]	16.0 [7.0, 29.0]	20.0 [12.0, 30.0]	<b>&lt;0.001</b>
<b>Age group</b>	0-4years	1875 (14.4)	744 (13.8)	1100 (15.5)	31 (5.8)	<b>&lt;0.001</b>
	5-9years	2088 (16.0)	817 (15.2)	1202 (16.9)	69 (12.9)	
	10-14years	1483 (11.4)	588 (10.9)	841 (11.8)	54 (10.1)	
	15-29years	3936 (30.2)	1707 (31.8)	2005 (28.2)	224 (41.8)	
	30-44years	2024 (15.6)	897 (16.7)	1039 (14.6)	88 (16.4)	
	45-59years	737 (5.7)	302 (5.6)	397 (5.6)	38 (7.1)	
	60+years	376 (2.9)	143 (2.7)	224 (3.2)	9 (1.7)	
	Unknown	495 (3.8)	176 (3.3)	296 (4.2)	23 (4.3)	
	<b>Educational status</b>	Educated	2015 (15.5)	875 (16.3)	1047 (14.7)	
No education	10999 (84.5)	4499 (83.7)	6057 (85.3)	443 (82.6)		

236

**Table 1 Cont.**

Variable	Category	Overall	Unconfirmed	YFV Negative	YFV Positive	p-value
<b>Occupational setting</b>	Indoor	3413 (26.2)	1575 (29.3)	1688 (23.8)	150 (28.0)	<b>&lt;0.001</b>
	Outdoor	828 (6.4)	452 (8.4)	330 (4.6)	46 (8.6)	
	Unknown	8773 (67.4)	3347 (62.3)	5086 (71.6)	340 (63.4)	
<b>Occupation status</b>	Artisan/trader	371 (2.9)	183 (3.4)	176 (2.5)	12 (2.2)	<b>&lt;0.001</b>
	Home-based/office work	5376 (41.3)	2095 (39.0)	3106 (43.7)	175 (32.6)	
	Healthcare worker	44 (0.3)	17 (0.3)	26 (0.4)	1 (0.2)	
	Hunter/butcher/animal trade/farmer	798 (6.1)	436 (8.1)	318 (4.5)	44 (8.2)	
	Student	1323 (10.2)	606 (11.3)	645 (9.1)	72 (13.4)	
<b>Traveled within last 2 weeks</b>	Unemployed	5102 (39.2)	2037 (37.9)	2833 (39.9)	232 (43.3)	
	No	12755 (98.0)	5228 (97.3)	7022 (98.8)	505 (94.2)	<b>&lt;0.001</b>
	Yes	259 (2.0)	146 (2.7)	82 (1.2)	31 (5.8)	
<b>Vaccination status</b>	Unknown	9031 (69.4)	3492 (65.0)	5093 (71.7)	446 (83.2)	<b>&lt;0.001</b>
	Unvaccinated	2248 (17.3)	1241 (23.1)	981 (13.8)	26 (4.9)	
	Vaccinated	1735 (13.3)	641 (11.9)	1030 (14.5)	64 (11.9)	

Numbers are N(%) unless otherwise noted.

IQR = interquartile range.

Overall refers to all suspected YF cases reported throughout the study period.

Unconfirmed refers to suspected cases that were not confirmed by either serology or PCR.

Statistically significant p-values are in bold text.

237

238 The highest peak of case reporting and YFV case positivity were seen around Week 43 in the 2020  
 239 epidemic season (**Fig 1A**). The highest incidence of involvement of vaccinated cases was seen  
 240 during week 34-43 of the 2019 epidemic season (**Fig 1B**). The initiation of YF vaccination  
 241 (reactive and preventive) campaign between 2017 and 2018 apparently resulted in a flattening of  
 242 the 2018 epidemic peak (around week 35-40).

243

244 **Fig 1. Time trends of incidence of YF cases in Nigeria, 2017-2021.** Lines indicate weekly mean  
 245 incidence. In: (A) average weekly incidence were stratified by laboratory test result; (B) average  
 246 weekly incidence disaggregated by vaccination status. Light blue histogram background is the  
 247 epidemic curve of all suspected cases.

248

249 The North-west geo-political zone presented a somewhat characteristic trend of case incidence  
 250 pattern with several peaks seen over the entire period, usually during the dry season (highest peak  
 251 seen between week 34 and 43 of the 2019 epidemic season), which were much larger in magnitude

252 and longer in duration, except during the 2020 epidemic season (Fig 2A). This pattern was found  
253 to be inherent in the Sahel Savannah ecological zone (Fig 2B).

254

255 **Fig 2. Trends of incidence of reported YF cases in Nigeria, 2017-2021.** Lines indicate weekly  
256 mean incidence. In: (A) cases were disaggregated by geo-political zone; and (B) cases were  
257 disaggregated by ecological zone. Light blue histogram background is the epidemic curve of all  
258 reported cases.

259

260 The 2020 epidemic season presented the most distinct trend pattern throughout the entire period  
261 in which the highest peak incidence seen in the South-east geo-political zone reflected the outbreak  
262 pattern of the Derived Savannah. Annually, YF case reporting increased progressively from about  
263 the middle of the rainy season between June and July with the peak incidence seen sometime  
264 between September and November (Figs 3A and B).

265

266 **Fig 3. Seasonality plot of reported Yellow fever cases in Nigeria, 2017-2021.** (A) all suspected  
267 cases, (B) YFV confirmed cases. Cases were aggregated by month in a line plot over the entire  
268 period.

269

270 Overall case reporting was higher during the pre-pandemic era (2016-2019; 58.3%) while YFV  
271 positive case was more during the COVID-19 pandemic era (2020-2021; 55.0%; <0.001) (Table  
272 1).

273

274

## 275 **Socio-demographic and clinical characteristics**

276 Between July 1, 2017 and December 31, 2021, Nigeria recorded a total of 13,014 suspected YF  
277 cases, of which 7640 (58.7%) had laboratory confirmation by either serology or RT-PCR. Overall  
278 YFV case positivity was 7.02% (536/7640). Median age was higher among YFV positive cases  
279 (median= 20.0 years; IQR= 12.0 – 30.0 years) (Table 1). The most affected age group were those  
280 15-29 years, who also accounted for about 30.0% (64,883,373) of the total population and about  
281 32.0% (3936) of all suspected cases (Fig 4A). They were also the most unvaccinated group (Fig  
282 4C) and had the largest proportion of persons with unknown vaccination status (Fig 4D).

283

284 **Fig 4. Age-sex pyramid of Yellow fever cases in Nigeria, 2017-2021.** From left to right: (A) all  
285 reported cases, (B) vaccinated cases, (C) unvaccinated cases, and (D) cases of unknown  
286 vaccination status. The percentage of cases were superimposed on country age-sex population  
287 structure. Pink = female and blue = male. The light-shaded bars indicate country demographic age-  
288 sex structure.

289

290 Cases were mostly males (all: 56.5%; positive: 63.6%; negative: 54.8%; unconfirmed: 58.1%;  
291  $p<0.001$ ). Case reporting was higher in the Sudan Savannah (28.2%) whereas YFV positive case  
292 was more in the Derived Savannah (38.8%,  $p<0.001$ ) ecological zone. They were predominantly  
293 of uneducated (all: 84.5%; positive: 82.6%; negative: 85.3%; unconfirmed: 83.7%;  $p=0.029$ );  
294 mostly home-based or working in office setting (41.3%), but the unemployed had higher YFV case  
295 positivity (43.3%,  $p<0.001$ ). They were largely of unknown vaccination status (all: 69.4%;  
296 positive: 83.2%; negative: 71.7%; unconfirmed: 65.0%;  $p<0.001$ ) (Table 1).

297 Clinical symptoms commonly presented among reported cases were fever (63.9%), jaundice  
298 (28.7%), headache (16.1%), fatigue (11.6%), dark urine (7.1%), and vomiting (6.1%). YFV  
299 positive cases presented more with fever (70.9%) and had a higher admission rate (11.9%) (Fig 4).

300

301 **Fig 5. Clinical characteristics of reported Yellow fever cases in Nigeria, 2017-2021.** (A) all  
302 reported cases, and (B) YFV confirmed cases. Yellow bar = symptom is present (Yes), purple bar  
303 = symptom not presented, and green bar = missing data.

304

### 305 **Seasonal, geographical, socio-demographic, and clinical factors** 306 **associated with YFD.**

307 Factors associated with YFD are shown in Table 2. Independent predictors of YFD were male sex  
308 compared to female (aOR: 2.36, 95% CI: 1.45–3.91;  $p < 0.001$ ); age group being 15-29 years  
309 compared to under-fives (aOR: 4.13, 95% CI: 1.59–13.00,  $p = 0.007$ ); residing within the Derived  
310 Savannah, Lowland/Mangrove/Freshwater rainforest, and the Guinea Savannah/Jos Plateau  
311 compared to the Sahel/Sudan Savannah (aOR: 30.10, 95% CI: 11.50–104.00; aOR: 8.84, 95% CI:  
312 3.24–31.10; aOR: 6.13, 95% CI: 1.90–23.50 respectively,  $p < 0.001$ ). Working in outdoor setting  
313 was associated with YFD but not statistically significant (aOR: 1.76, 95% CI: 0.96–3.22,  $p = 0.067$ ).  
314 Clinical predictor of YFD was presenting with vomiting (aOR: 2.62, 95% CI: 1.39–4.83;  $p = 0.002$ ).  
315 The rainy season was protective against YFD (aOR: 0.32, 95% CI: 0.19–0.52,  $p < 0.001$ ).

316

317

318

319 **Table 2. Seasonal, geographical, socio-demographic, and clinical factors associated with YFD**  
 320 **among reported cases in Nigeria, 2017-2021.**

Characteristic	Univariate				Multivariable		
	Total	Crude OR	95% CI	p-value	Adjusted OR	95% CI	p-value
<b>Epidemic season</b>	7,640						
2017		1.00	Ref	<0.001			
2018		0.36	0.15, 0.77				
2019		2.97	1.96, 4.72				
2020		3.82	2.53, 6.07				
2021		1.84	1.14, 3.06				
<b>Annual quarter</b>	7,640						
First quarter		3.55	2.21, 6.01	<0.001			
Second quarter		1.00	Ref				
Third quarter		6.13	3.87, 10.3				
Fourth quarter		16.4	10.6, 27.2				
<b>Epidemic period</b>	7,640						
Pre-pandemic		1.00	Ref	<0.001			
Pandemic		1.52	1.27, 1.81				
<b>Climatic season</b>	7,640						
Dry season		1.00	Ref	<0.001	1.00	Ref	<0.001
Rainy season		0.59	0.50, 0.71		0.32	0.19, 0.52	
<b>Geo-political zone</b>	7,640						
North-west		1.00	Ref	<0.001			
North-central		3.04	2.09, 4.49				
North-east		5.60	3.94, 8.10				
South-east		4.64	3.30, 6.66				
South-south		4.58	3.21, 6.67				
South-west		1.80	1.16, 2.81				
<b>Ecological zone</b>	7,640						
Sahel/Sudan Savannah		1.00	Ref	<0.001	1.00	Ref	<0.001
Derived Savannah		4.34	3.27, 5.84		30.10	11.50, 104.00	
Lowland/Freshwater/Mangrove rainforest		2.84	2.10, 3.88		8.84	3.24, 31.10	
Guinea Savannah/Jos Plateau		4.55	3.35, 6.25		6.13	1.90, 23.50	
<b>Sex</b>	7,611						
Female		1.00	Ref	<0.001	1.00	Ref	<0.001
Male		1.42	1.19, 1.71		2.36	1.45, 3.91	
<b>Age group</b>	7,321						
0-4 years		1.00	Ref	<0.001	1.00	Ref	0.007
5-9 years		2.04	1.34, 3.18		1.94	0.65, 6.57	
10-14 years		2.28	1.46, 3.61		1.96	0.60, 6.99	
15-29 years		3.96	2.75, 5.92		4.13	1.59, 13.0	
30-44 years		3.01	2.00, 4.63		2.36	0.76, 8.39	
45-59 years		3.40	2.09, 5.57		2.84	0.79, 11.2	
60+ years		1.43	0.63, 2.92		1.33	0.15, 8.38	
<b>Educational status</b>	7,640						
Educated		Ref	1.00	0.100			
No education		0.82	0.66, 1.04				
<b>Occupational group</b>	7,640						
Home/office worker		1.00	Ref	<0.001			
Unemployed		1.45	1.19, 1.78				
Student		1.98	1.48, 2.63				
Butcher/hunter/farmer		2.46	1.71, 3.45				
Artisan/trader		1.21	0.63, 2.12				
Healthcare worker		0.68	0.04, 3.24				
<b>Occupation setting</b>	2,214						
Indoor		1.00	Ref	<0.001	1.00	Ref	0.067
Outdoor		2.30	1.71, 3.11		1.76	0.96, 3.22	
<b>Traveled within last 2 weeks</b>	7,640						
No		1.00	Ref	<0.001			
Yes		5.26	3.40, 7.94				
<b>Vaccination status</b>	7,640						



321

Table 2 Cont.

Characteristic	Univariate				Multivariable		
	Total	Crude OR	95% CI	p-value	Adjusted OR	95% CI	p-value
		1.00	Ref	<b>&lt;0.001</b>	1.00	Ref	0.057
Unknown		0.30	0.20, 0.44		0.51	0.25, 1.00	
Unvaccinated		0.71	0.54, 0.92		1.01	0.55, 1.82	
Vaccinated							
<b>Anorexia</b>	3,061						
No		1.00	Ref	0.14			
Yes		0.68	0.39, 1.10				
<b>Dark urine</b>	2,952						
No		1.00	Ref	<b>0.022</b>			
Yes		0.55	0.32, 0.89				
<b>Fatigue</b>	3,112						
No		1.00	Ref	<b>0.016</b>			
Yes		1.45	1.07, 1.94				
<b>Hemorrhagic symptoms</b>	2,992						
No		1.00	Ref	<b>&lt;0.001</b>			
Yes		5.18	1.83, 12.9				
<b>Vomiting</b>	3,095						
No		1.00	Ref	<b>&lt;0.001</b>	1.00	Ref	<b>0.002</b>
Yes		2.51	1.76, 3.52		2.62	1.39, 4.83	

OR = Odds Ratio

CI = Confidence Interval

Statistically significant p-values are in bold text.

322

323 Considering the higher YFV positivity rate among vaccinated cases compared to the unvaccinated  
 324 and the fact that being unvaccinated emerged as a protective factor in our final multivariate logistic  
 325 regression analysis, we further disaggregated the dataset by vaccination status and analyzed the  
 326 predictors of YFD by sub-group. The odds of YFD were higher among the unvaccinated and those  
 327 with unknown vaccination status compared to those with previous YF vaccination (Table 3).  
 328 Factors associated with YFD among those with unknown vaccination status were the first, third  
 329 and last quarter of the year compared to the second quarter (OR: 4.27, 95% CI: 2.22–9.26; OR:  
 330 9.24, 95% CI: 4.95–19.80, and OR: 24.50, 95% CI: 13.38–51.60, p<0.001); the covid-19  
 331 pandemic period (OR: 1.84, 95% CI: 1.51–2.23; p<0.001); the rainy season (OR: 1.39, 95% CI:  
 332 1.12–1.71; p=0.003); male sex (OR: 1.45, 95% CI: 1.19–1.78; p<0.001); age being 5 years or older  
 333 compared to being four years and below (5-9 year: OR: 2.16, 95% CI: 1.33–3.62; 10-14 years:  
 334 OR: 2.60, 95% CI: 1.57–4.41; 15-29 years: OR: 4.37, 95% CI: 2.88-6.98; 30-44 years: OR: 2.96,  
 335 95% CI: 1.86–4.89; 45-59 years: OR: 3.56, 95% CI: 2.07–6.21; p<0.001); residing within the

336 Derived Savannah, the Lowland/Freshwater/Mangrove rainforest, and the Guinea Savannah/Jos  
 337 Plateau compared to the Sahel/Sudan Savannah (OR: 3.78, 95% CI: 2.80–5.16, OR: 2.01, 95%  
 338 CI: 1.45–2.83, OR: 4.35, 95% CI: 3.15–6.07 respectively;  $p < 0.001$ ); being unemployed, student,  
 339 and butcher/hunter/farmer (OR: 1.26, 95% CI: 1.01–1.57; OR: 2.40, 95% CI: 1.69–3.35; and OR:  
 340 3.33, 95% CI: 2.15–5.03;  $p < 0.001$ ); working in outdoor settings (OR: 2.21, 95% CI: 1.55–3.17;  
 341  $p < 0.001$ ); having traveled within last two weeks preceding onset (OR: 5.53, 95% CI: 3.45–8.65),  
 342 presenting with fatigue, jaundice, and vomiting (OR: 1.97, 95% CI: 1.38–2.77,  $p < 0.001$ ; OR: 1.50,  
 343 95% CI: 1.12–2.02;  $p = 0.007$ ; and OR: 2.37, 95% CI: 1.55–3.56,  $p < 0.001$ ).

344 **Table 3. Seasonal, geographical, socio-demographic, clinical factors associated with YFD**  
 345 **among reported cases in Nigeria, 2017-2021 disaggregated by vaccination status.**

Characteristic	Vaccinated				Unvaccinated				Unknown status			
	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value
<b>Annual quarter</b>	1,094				1,007				5,539			
First quarter		3.51	1.61, 8.80	<b>0.017</b>		1.32	0.29, 6.73	<b>&lt;0.001</b>		4.27	2.22, 9.26	<b>&lt;0.001</b>
Second quarter		1.00	Ref			1.00	Ref			1.00	Ref	
Third quarter		2.97	1.26, 7.79			2.28	0.60, 10.9			9.27	4.95, 19.8	
Fourth quarter		2.48	0.94, 6.95			13.2	4.16, 58.5			24.5	13.3, 51.6	
<b>Epidemic period</b>	1,094				1,007				5,539			
Pre-pandemic		1.00	Ref	0.800		1.00	Ref	0.800		1.00	Ref	<b>&lt;0.001</b>
Pandemic		0.94	0.56, 1.56			1.10	0.50, 2.62			1.84	1.51, 2.23	
<b>Climatic season</b>	1,094				1,007				5,539			
Dry season		1.00	Ref	0.900		1.00	Ref	0.800		1.00	Ref	<b>0.003</b>
Rainy season		1.06	0.56, 1.88			0.91	0.37, 2.05			1.39	1.12, 1.71	
<b>Geographical region</b>	1,094				1,007				5,539			
North		1.00	Ref	<b>0.007</b>		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	0.200
South		2.37	1.31, 4.60			6.51	2.89, 16.0			1.15	0.94, 1.39	
<b>Ecological zone</b>	1,094				1,007				5,539			
Sahel/Sudan Savannah		1.00	Ref	<b>0.002</b>		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	<b>&lt;0.001</b>
Derived Savannah		2.77	0.89, 12.1			48.1	9.65, 874			3.78	2.80, 5.16	
Lowland/Freshwater/Mangrove rainforest		6.39	2.27, 26.7			19.1	3.05, 367			2.01	1.45, 2.83	
Guinea Savannah/Jos Plateau		3.34	0.98, 15.3			16.6	2.64, 318			4.35	3.15, 6.07	
<b>Sex</b>	1,092				1,004				5,515			
Female		1.00	Ref	0.800		1.00	Ref	0.065		1.00	Ref	<b>&lt;0.001</b>
Male		1.08	0.65, 1.81			2.40	1.00, 6.68			1.45	1.19, 1.78	
<b>Age group</b>	1,012				1,000				5,309			
0-4 years		1.00	Ref	<b>0.031</b>		1.00	Ref	<b>0.045</b>		1.00	Ref	<b>&lt;0.001</b>
5-9 years		1.15	0.42, 3.27			5.03	0.80, 97.0			2.16	1.33, 3.62	
10-14 years		1.37	0.46, 4.08			1.28	0.05, 32.6			2.60	1.57, 4.41	
15-29 years		2.58	1.13, 6.65			3.88	0.70, 72.2			4.37	2.88, 6.98	
30-44 years		2.88	1.12, 7.93			6.16	1.04, 117			2.96	1.86, 4.89	
45-59 years		0.69	0.04, 4.03			10.4	1.30, 213			3.56	2.07, 6.21	
60+ years		No data				6.78	0.26, 176			1.40	0.58, 3.05	
<b>Educational status</b>	1,094				1,007				5,539			
Educated		1.00	Ref	0.600		1.00	Ref	0.140		1.00	Ref	<b>0.002</b>
No education		0.86	0.51, 1.52			0.55	0.25, 1.24			0.64	0.48, 0.86	
<b>Occupational group</b>	1,094				1,007				5,539			
Home/office worker		1.00	Ref	<b>0.019</b>		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	<b>&lt;0.001</b>
Unemployed		2.09	1.13, 3.92			2.13	0.59, 7.75			1.26	1.01, 1.57	

346

**Table 3 Cont.**

Characteristic	Vaccinated				Unvaccinated				Unknown status			
	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value
Student		1.87	0.94, 3.68			3.83	1.14, 13.5			2.40	1.69, 3.35	
Butcher/hunter/farmer		1.38	0.32, 4.21			6.78	2.37, 22.1			3.33	2.15, 5.03	
Artisan/trader		0.50	0.03, 2.48			No data				1.81	0.90, 3.31	
Healthcare worker		7.83	0.38, 64.3			No data				No data		
<b>Occupational setting</b>	526				604				1,084			
Indoor		1.00	Ref	>0.900		1.00	Ref	<b>0.011</b>		1.00	Ref	<b>&lt;0.001</b>
Outdoor		0.98	0.42, 2.15			3.43	1.36, 9.34			2.21	1.55, 3.17	
<b>Traveled within last two weeks</b>	1,094				1,007				5,539			
No		1.00	Ref	0.500		1.00	Ref	<b>0.020</b>		1.00	Ref	<b>&lt;0.001</b>
Yes		2.03	0.11, 11.3			6.21	0.94, 24.1			5.53	3.45, 8.65	
<b>Fatigue</b>	630				647				1,835			
No		1.00	Ref	0.300		1.00	Ref	0.084		1.00	Ref	<b>&lt;0.001</b>
Yes		0.55	0.16, 1.44			2.24	0.89, 5.73			1.97	1.38, 2.77	
<b>Jaundice</b>	659				677				1,864			
No		1.00	Ref	0.130		1.00	Ref	0.130		1.00	Ref	<b>0.007</b>
Yes		1.89	0.87, 4.54			0.47	0.18, 1.36			1.50	1.12, 2.02	
<b>Hemorrhagic symptoms</b>	618				623				1,751			
No		1.00	Ref	0.06		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	0.120
Yes		9.75	0.45, 105			23.6	2.96, 151			2.84	0.63, 9.39	
<b>Vomiting</b>	636				649				1,810			
No		1.00	Ref	<b>0.044</b>		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	<b>&lt;0.001</b>
Yes		2.61	0.94, 6.27			5.18	1.85, 13.6			2.37	1.55, 3.56	

cOR = Crude Odds Ratio

CI = Confidence Interval

Vaccinated are cases with previous YF vaccination.

Unvaccinated had no previous YF vaccination.

Unknown status are cases whose YF vaccination history was not known.

Statistically significant p-values are in bold text.

347

348

349 The predictors of YFD among those with previous YF vaccination were the first quarter of the  
 350 year compared to the second (aOR: 4.04, 95% CI: 1.48–12.95; p=0.010), residing in the southern  
 351 region (aOR: 14.03, 95% CI: 4.09–88.27; p<0.001). Clinical symptoms such as jaundice (aOR:  
 352 2.05, 95% CI: 0.88–5.25; p=0.110) and vomiting (aOR: 2.29, 95% CI: 0.75–6.25; p=0.120) were  
 353 associated with YFD among the vaccinated but not statistically significant. Predictors among the  
 354 unvaccinated were male sex (aOR: 6.35, 95% CI: 1.66–32.16; p=0.012), residing in the southern  
 355 region (aOR: 76.64, 95% CI: 13.57–1465.89; p<0.001), working in outdoor settings (aOR: 3.11, 95%  
 356 CI: 0.91–12.03; p=0.079), presenting with fatigue (aOR: 3.87, 95% CI: 1.10–15.08; p=0.039),  
 357 hemorrhagic symptoms (aOR: 368.00, 95% CI: 14.29–14759.72; p<0.001), and vomiting (aOR: 6.53,  
 358 95% CI: 1.57–27.23; p= 0.009). Predictors of YFD among cases with unknown vaccination status

359 were the third and fourth quarter of the year (aOR: 4.44, 95% CI: 1.92–12.11; aOR: 3.38, 95% CI:  
360 1.08–10.90; p=0.001); age being 15 years or older (aOR: 1.87, 95% CI: 1.17–3.10, p=0.012);and  
361 residing within the Derived Savannah and the Guinea Savannah/Jos Plateau (aOR: 7.09, 95% CI:  
362 3.35–17.45 and aOR: 5.24, 95% CI: 2.41–13.14 respectively; p<0.001) Fig 6.

363

364 **Fig 6. Seasonal, geographical, socio-demographic, clinical predictors of YFD among reported**  
365 **cases in Nigeria, 2017-2021 disaggregated by vaccination status.**

366 (A) Unvaccinated (B) Unknown vaccination status. The first column shows the explanatory  
367 variables, second column show the levels and third column is the adjusted odds ratios with  
368 corresponding confidence intervals.

369

370 **Factors associated with being unvaccinated (barriers to YF**  
371 **vaccination)**

372 Information on vaccination status was available for 3983 out 13014 reported cases, of which 1735  
373 (13.3%) were vaccinated, 2248 (17.3) were unvaccinated, and 9031 (69.4%) were of unknown  
374 status (Table 1). The most unvaccinated age group were those 15-29 years, which also accounted  
375 for 30.0% of the total population, 32.0 % of unvaccinated cases, and 27.0% of cases of unknown  
376 vaccination status (Fig 4 and S1 Table). A comparison of the characteristics of the cases by  
377 vaccination status is shown in S1 Table. Independent predictors of being unvaccinated for YF,  
378 irrespective of laboratory test status, were the rainy season compared to the dry season (aOR: 1.29,  
379 95% CI: 1.11-1.66, p=0.003); being 15years or older compared to under-five (15-29 years: aOR:  
380 2.06, 95% CI: 1.51-2.83; 30-44 years: aOR: 2.11, 95% CI: 1.45-3.07; 45-59 years: aOR: 2.72, 95%  
381 CI: 1.63-4.58; 60+ years: aOR: 6.55, 95% CI: 2.76-17.50; p<0.001 ); residing in the northern  
382 region compared to the southern region (aOR: 3.71, 95% CI: 3.01-4.58, p<0.001); and occupation  
383 being either butcher, farmer or hunter compared to being home-based/officer worker (aOR: 2.30,  
384 95% CI: 1.52-3.50, p<0.001). Working in outdoor setting was protective against being  
385 unvaccinated (aOR: 0.46, 95% CI: 0.31-0.69, p<0.001) (Table 4).

386

387

388

389

390

391

392

393 **Table 4. Seasonal, geographical, and socio-demographic factors associated with non-vaccination**  
 394 **among reported YF cases in Nigeria, 2017-2021.**

Characteristic	Univariate				Multivariable		
	Total	Crude OR	95% CI	p-value	Adjusted OR	95% CI	p-value
<b>Epidemic period</b>	3,983						
Pre-pandemic		1.00	Ref	0.400			
Pandemic		1.06	0.93, 1.20				
<b>Climatic season</b>	3,983						
Dry season		1.00	Ref	0.063	1.00	Ref	<b>0.013</b>
Rainy season		1.15	0.99, 1.33		1.29	1.05, 1.57	
<b>Sex</b>	3,971						
Female		1.00	Ref	0.200			
Male		1.09	0.96, 1.24				
<b>Age group</b>	3,862						
0-4 years		1.00	Ref	<b>&lt;0.001</b>	1.00	Ref	<b>&lt;0.001</b>
5-9 years		0.85	0.69, 1.05		0.92	0.66, 1.28	
10-14 years		1.08	0.86, 1.37		1.25	0.86, 1.82	
15-29 years		1.63	1.34, 1.97		2.06	1.51, 2.83	
30-44 years		1.59	1.27, 2.00		2.11	1.45, 3.07	
45-59 year		1.58	1.13, 2.22		2.72	1.63, 4.58	
65+ years		2.28	1.38, 3.89		6.55	2.76, 17.5	
<b>Geographical region</b>	3,983						
South		1.00	Ref	<b>&lt;0.001</b>	1.00	Ref	<b>&lt;0.001</b>
North		4.66	4.07, 5.35		3.71	3.01, 4.58	
<b>Educational status</b>	3,983						
Educated		1.00	Ref	<0.001	1.00	Ref	0.700
No education		1.39	1.20, 1.59		1.04	0.82, 1.33	
<b>Occupational status</b>	3,983						
Home/office worker		1.00	Ref	<b>&lt;0.001</b>	1.00	Ref	<b>&lt;0.001</b>
Unemployed		1.00	0.85, 1.17		-	-	
Student		0.54	0.45, 0.64		0.62	0.47, 0.83	
Butcher/hunter/farmer		1.91	1.51, 2.42		2.30	1.52, 3.50	
Artisan/trader		0.80	0.58, 1.11		1.45	0.90, 2.37	
Healthcare worker		2.12	0.98, 5.09		1.42	0.63, 3.54	
<b>Occupational setting</b>	2,119						
Indoor		1.00	Ref	<b>0.003</b>	1.00	Ref	<b>&lt;0.001</b>
Outdoor		1.32	1.10, 1.59		0.42	0.28, 0.62	

OR = Odds Ratio

CI = Confidence Interval

Statistically significant p-values are in bold text.

395

396

397 To further investigate the effect of the COVID-19 pandemic on YF vaccination, we disaggregated

398 the analysis by laboratory test status. The COVID-19 pandemic period was associated with being

399 unvaccinated among YFV positive (OR: 2.43, 95% CI: 0.96-6.48, p=0.066) and negative cases

400 (OR: 2.06, 95% CI: 1.73-2.47, p<0.001) compared to the pre-pandemic period, just as working in  
 401 outdoor settings in comparison to working indoors (OR: 3.81, 95% CI: 1.16-13.6, p=0.032) among  
 402 YFV positive cases (Table 5).

403 **Table 5. Factors associated with non-vaccination among reported Yellow fever cases in**  
 404 **Nigeria, 2017-2021 disaggregated by laboratory test status.**

Characteristic	Positive cases				Negative cases				Unconfirmed cases			
	N	cOR	95% CI	p-value	N	cOR	95% CI <sup>1</sup>	p-value	N	cOR	95% CI	p-value
<b>Epidemic period</b>	90				2,011				442			
Pre-pandemic		1.00	Ref	0.066		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	0.120
Pandemic		2.43	0.96, 6.48			2.06	1.73, 2.47			0.34	0.22, 0.54	
<b>Climatic season</b>	90				2,011				442			
Dry season		1.00	Ref			1.00	Ref			1.00	Ref	0.060
Rainy season		1.45	0.51, 3.96	0.500		1.69	1.39, 2.06	<b>&lt;0.001</b>		0.59	0.34, 1.03	
<b>Geographical region</b>	90				2,011				442			
South		1.00	Ref	0.300		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	<b>&lt;0.001</b>
North		1.74	0.60, 4.86			4.79	3.96, 5.80			6.71	4.23, 10.8	
<b>Sex</b>	88				2,008				439			
Female		1.00	Ref	0.110		1.00	Ref	0.600		1.00	Ref	0.100
Male		2.33	0.85, 7.14			1.05	0.88, 1.25			1.43	0.93, 2.19	
<b>Age group</b>	83				1,929				1,850			
0-4 years		1.00	Ref	0.053		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	<b>&lt;0.001</b>
5-9 years		3.89	0.47, 83.8			0.89	0.66, 1.19			0.82	0.60, 1.11	
10-14 years		1.00	0.03, 28.8			1.07	0.78, 1.48			1.21	0.85, 1.73	
15-29 years		2.55	0.36, 51.5			1.70	1.30, 2.22			1.67	1.26, 2.22	
30-44 years		3.50	0.46, 73.3			1.64	1.19, 2.26			1.67	1.18, 2.36	
45-59 years		21.0	1.33, 913			1.39	0.87, 2.25			1.68	1.03, 2.81	
60+ years			No data			2.03	1.02, 4.17			2.48	1.16, 5.95	
<b>Educational status</b>	90				2,011				1,882			
Educated		1.00	Ref	0.300		1.00	Ref	0.800		1.00	Ref	<b>&lt;0.001</b>
No education		0.62	0.24, 1.61			0.98	0.80, 1.19			2.10	1.70, 2.60	
<b>Occupational group</b>	90				2,011				442			
Home-based/Office worker		1.00	Ref	<b>0.002</b>		1.00	Ref	<b>&lt;0.001</b>		1.00	Ref	<b>&lt;0.001</b>
Unemployed		0.87	0.21, 3.55			0.85	0.68, 1.07			2.02	1.11, 3.83	
Student		1.50	0.38, 6.09			0.73	0.57, 0.94			0.21	0.11, 0.41	
Butcher/farmer/hunter		13.3	2.92, 79.5			2.72	1.93, 3.88			0.86	0.45, 1.73	
Artisan/Trader		Missing				0.90	0.58, 1.40			0.38	0.11, 1.37	
Healthcare worker		Missing				6.70	2.27, 28.7			0.32	0.01, 8.10	
<b>Occupational setting</b>	48				1,082				225			
Indoor		1.00	Ref	<b>0.032</b>		1.00	Ref	0.500		1.00	Ref	0.150
Outdoor		3.81	1.16, 13.6			1.09	0.85, 1.41			1.52	0.87, 2.70	

cOR = Crude Odds Ratio

CI = Confidence Interval

Positive cases are YFV laboratory confirmed cases of YF.

Negative cases are suspected cases that tested negative for YFV.

Unconfirmed cases are suspected cases that had no laboratory confirmation.

Statistically significant p-values are in bold text.

405

406

407 More independent predictors were seen among YFV negative cases, which include the COVID-  
408 19 pandemic period (aOR: 1.40, 95% CI: 1.14-1.72, p=0.002), age group being 15-29, 30-44, 60+  
409 years (aOR: 1.81, 95% CI: 1.28-2.57; aOR: 1.79, 95% CI: 1.19-2.69; and aOR: 2.25, 95% CI:  
410 1.03-5.02; p=0.001), residing in the northern region (aOR: 4.39, 95% CI: 3.58-5.40, p<0.001); and  
411 occupation being butcher/farmer/hunter, and health worker (aOR: 1.63, 95% CI: 1.08-2.47; aOR:  
412 4.03, 95% CI: 1.33-17.47; p=0.021) (**Fig 7**).

413

414 **Fig 7. Seasonal, geographical, and socio-demographic predictors non-vaccination among**  
415 **reported cases in Nigeria, 2017-2021 disaggregated by laboratory test status.**

416 (A) Negative (B) Unconfirmed cases. The first column shows the explanatory variables, second  
417 column show the levels and third column is the adjusted odds ratios with corresponding confidence  
418 intervals.

419

420 Among YFV positive cases, independent predictors of being unvaccinated were COVID-19  
421 pandemic period (aOR: 3.08, 95% CI: 0.86-12.55, p=0.09) and working in outdoor settings (aOR:  
422 3.89, 95% CI: 1.13-14.64, p=0.03).

423

424

425

426

427



## 428 **Discussion**

429 Recommended control strategies for YF under the WHO EYE strategy include effective and timely  
430 surveillance, strengthening laboratory services, adequate routine immunization coverage and a  
431 comprehensive response to outbreaks of YF [11,17,29,30]. In Nigeria, YF surveillance is a passive,  
432 health facility-based, case-based, laboratory-based, surveillance system [18]. Most suspected cases  
433 reported during the study period were not confirmed by laboratory test, which may be because  
434 cases did not present early enough at health facilities to enable prompt detection of YFV by RT-  
435 PCR within the ten-day window period for detection of the viral genome in blood samples.  
436 Logistical challenges associated with sample transportation from Nigeria to the Regional  
437 Reference Laboratory in Dakar, Senegal for confirmation of presumptive positive and inconclusive  
438 RT-PCR negative samples by PRNT may be another possible reason [18]. Late presentation of  
439 cases at health facility may have also contributed to the large proportion of suspected cases that  
440 tested negative for YFV despite meeting the case definition. These challenges may be surmounted  
441 by investment in community-based surveillance to enable prompt case detection and building in-  
442 country capacity for full complement of serological testing. In Côte d'Ivoire, an eight-fold increase  
443 in suspected YF case reporting was documented following implementation of community-based  
444 surveillance [31].

445 The odds of YFD increased significantly from the 2017 epidemic season through the 2020 season,  
446 which was followed by an abrupt decrease in the 2021 season. The 2020 epidemic season coincided  
447 with the commencement of the COVID-19 pandemic. Thus, the decrease in case reporting  
448 observed during the pandemic period may be a pointer to the disruptive effect of the COVID-19  
449 pandemic on YF surveillance activities in Nigeria [32]. The pandemic resulted in the conversion  
450 of several public hospitals to COVID-19 treatment centers in Nigeria and elicited patients' apathy

451 towards hospital attendance [33]. We have shown that cases were about twice as likely to be  
452 unvaccinated for YF during the pandemic period. Ayobami et al (2023) had reported that the  
453 COVID-19 pandemic was associated with reduction in care seeking for children and clinic  
454 attendance for childhood immunization [33]. Similarly, Ribeiro da Silva et al (2022) reported a  
455 reduction in the number of YF vaccine doses administered in Brazil during the pandemic period  
456 compared to the pre-pandemic era [34].

457 Our study has shown that YF outbreaks in Nigeria followed a distinct seasonal pattern in which  
458 case incidence followed the rainy season progression. Previous studies in Uganda and Brazil have  
459 reported a rainy season driven YF outbreak pattern [35,36]. The YF mass vaccination campaigns  
460 implemented in Nigeria between 2017 and 2019 were carried out in September of each year [5].  
461 We showed that cases were nearly twice more likely to be unvaccinated during the rainy season.  
462 The rainy season is the farming season in Nigeria, and farmers tend to spend most of their daytime  
463 in their farms during this time of year. Perhaps, commencing reactive vaccination early in the year  
464 (January - April) may increase the chances of getting more persons vaccinated, especially in areas  
465 where people are predominantly farmers or get involved in other forest-going occupation.

466 The most-at-risk population in this study were younger people, especially males. A similar study  
467 in Brazil reported males with a median age of 26 (range: 1-93) years, with the most affected age  
468 group being 20-29 years [23]. Ribeiro et al. also found males with a mean age of 29 years [37]. We  
469 found that cases in the age group 15-29 years had over two-fold odds of being unvaccinated and  
470 over four-fold odds of having YFD. Higher odds of YFD in males compared to females seen in  
471 this study has been attributed to occupation. A study in Uganda found that cases were  
472 predominantly males involved in rural agricultural activities in forested, swampy areas - an  
473 observation that has also been reported in Ethiopia [4,35].

474 The finding that cases without any travel history featured prominently in the epidemic suggests  
475 the presence of suitable conditions for YFV transmission locally [6]. However, persons with travel  
476 history had over five-fold odds of YFD compared to those that did not. Studies in Uganda [35] and  
477 Brazil [23] have incriminated traveling to YF endemic areas as risk factor for infection. This  
478 observation may not be unconnected with ecological characteristics. We found that the north-west  
479 geo-political zone, which straddles parts of the Guinea Savannah, Jos Plateau, Sahel Savannah,  
480 and the Sudan Savannah, reported the highest proportion of suspected cases but YFV positivity  
481 was highest in the south-east, which occupies parts of the Derived Savannah and the Lowland  
482 rainforest. Nomhwange et al (2021) had previously identified four epidemiological blocks of YFV  
483 spread in Nigeria, delineated by the geo-political zones: block 1 around the north-central; block 2  
484 in the south-south; block 3 in the south-east; and block 4 in the north-east [5]. The outbreak in the  
485 north-central block has been reported to spread into the north-west while the south-south block  
486 spreads into the south-west. Our findings, however, suggest that YFV transmission in these  
487 epidemiological blocks seemed to be related to the characteristics of the ecological zones that  
488 occupy the geo-political zones. We demonstrated for the first time, to our knowledge, the important  
489 contribution of the Derived Savannah, the Lowland/Freshwater/Mangrove rainforest, and the  
490 Guinea Savannah/Jos Plateau to YF epidemiology in Nigeria. Of concern is the double jeopardy  
491 of the higher odds YFD among unvaccinated and vaccinated persons in the  
492 Lowland/Freshwater/Mangrove rainforest ecological zone, which mainly occupy the south-south  
493 and south-west geo-political zones. We further showed that the odds of YFD in the Derived  
494 Savannah and the Guinea Savannah/Jos Plateau could be mitigated by adequate vaccination as  
495 these ecological zones largely lie in the northern region where cases had about five-fold odds of  
496 being unvaccinated compared to those in the southern region. A combination of human, reservoir,

497 and vector surveillance studies, in addition to the effects of human encroachment may provide  
498 further insight as to whether the varying degree of risk of YFD seen across the ecological zones in  
499 this study is driven by specific characteristics. In Brazil, where the YFV has demonstrated its  
500 ability to expand its geographic spread since 2016, human activities have been implicated as  
501 contributing factor [36,38].

502 Clinically, the viraemia phase of YF is characterized by fever, headache, chills, backache, fatigue,  
503 anorexia, nausea, and vomiting, whereas the toxaemic phase is marked by high fever, worsening  
504 headache, chills, muscle pain and signs of multiple organs and systems involvement. Hepatic  
505 coagulopathy leads to severe hemorrhagic manifestations [6]. These symptoms were manifested  
506 by the cases reported in this study, just as had also been reported in Uganda [35] and Brazil [2,39].  
507 YF is distinguished from other hemorrhagic fevers caused by viruses by the characteristic liver  
508 damage and presentation of jaundice [6]. Presenting fatigue, hemorrhagic symptoms and vomiting  
509 were significantly associated with YFD among the unvaccinated in our study. These factors may  
510 be important in strengthening YF case definition for the purpose of surveillance as well enhancing  
511 index of suspicion by clinicians and surveillance officers.

512 Vaccination is widely recognized as the most potent weapon to combat YF outbreaks. Following  
513 the resurgence of YF outbreak in 2017 in Nigeria, efforts were made to revamp up YF vaccination  
514 coverage. A total 45,648,243 persons of age less than 45 years were vaccinated across Nigeria  
515 through nine targeted reactive mass vaccination campaigns and three phased mass vaccination  
516 activities. [5]. The coverage achieved by these campaigns has not proved to adequately protect the  
517 population against YFV spread. In developing a strategy to enhance vaccine uptake in Nigeria, it  
518 is imperative that policy makers take into cognizance the potential barriers to YF vaccination. The  
519 independent predictors of being unvaccinated were the COVID-19 pandemic period, rainy season,

520 being 15 years or older, residing in northern Nigeria, being a butcher, farmer, or hunter and being  
521 a healthcare worker. To meet the 2026 target of the WHO EYE strategy, a review of the current  
522 policy on vaccination may be warranted to achieve sufficient coverage that could halt YFV  
523 transmission in Nigeria. A sizeable proportion of vaccinated cases were found to be positive for  
524 YFV and hospitalized, pointing to evidence of possible vaccine failure. A similar finding was  
525 reported by Tuboi et al (2007) in Brazil [23]. It may be difficult to pinpoint the reason for this. It  
526 is, however, known that the 17D YF vaccine is a live attenuated vaccine, and it is possible that its  
527 efficacy may be affected by factors related to proper handling, transport, storage, and usage, which  
528 could be challenging in resource-poor settings [23,40]. The involvement of vaccinated cases in the  
529 epidemic coincided with the period of implementation of reactive YF vaccination campaigns in  
530 Nigeria. The highest incidence was seen during the 2019 epidemic season, largely among cases  
531 15-29 year, working in indoor setting and residing largely in the Derived Savannah, Lowland  
532 rainforest, and the Sudan Savannah. This brings to the fore the crucial need for invest investments  
533 research tools that would enable understanding of the molecular epidemiology of the YFV in  
534 Nigeria.

## 535 **Limitation**

536 This study represents the first attempt in Nigeria to use multi-season national surveillance data to  
537 characterize the seasonal, geographical, socio-demographic, and clinical characteristics associated  
538 with YFD and to identify barriers to vaccination. The dataset was generated from different health  
539 facilities across Nigeria, making it quite representative. However, just like every other surveillance  
540 system, the national YF surveillance in Nigeria is not without limitations. First, it is a passive,  
541 health facility-based surveillance system, which relies on the judgement of clinicians to identify  
542 cases. Although, under outbreak conditions, an active and community-based component of the

543 surveillance system is activated. Considering the broad range of clinical presentation and  
544 symptoms associated with YF and the passive nature of the surveillance system, less severe cases  
545 may have been missed. However, clinicians and focal persons were trained regularly on using a  
546 WHO standard case definition to identify YF cases. Second, the national line list does not capture  
547 information on co-morbidities and pre-existing illnesses such as liver disease or previous toxic  
548 exposures such as alcohol consumption that may be confounding factors in YF disease. Third,  
549 there were issues related to data quality, including missing data, however, the development and  
550 deployment of the SORMAS platform, has strengthened the surveillance of diseases captured  
551 under the IDSR system, including YF in Nigeria, providing real time data entry and analysis. In  
552 any case, secondary data is useful for planning preventive measures, healthcare assessment, and  
553 research[41] . Findings from our study has the potential to be generalized as the dataset used had  
554 national representation, covering the six geo-political zones in Nigeria. However, it is important  
555 to note that the dataset used for the study was largely hospital-based. This implies that cases who  
556 felt they were not ill enough to access care in a health facility setting were completely missed by  
557 this study.

## 558 **Conclusion**

559 In conclusion, following its resurgence in 2017, YF outbreaks in Nigeria occurred annually with  
560 increasing odds of incidence until the 2020 epidemic season. Despite the epidemic following the rainy  
561 season pattern with the peak incidence seen between September and November annually, the odd of YFD  
562 was higher during the dry season. A combination of factors has proven to be important drivers of YF  
563 outbreaks in Nigeria. Although vaccination has proven to reduce the odds of YFD, the higher odds of  
564 YFD among previously vaccinated persons, especially those residing in the southern region suggests that  
565 inadequate vaccination alone may not explain the recurrent YF incidence in Nigeria, warranting further  
566 research using genomic surveillance tools. To improve YF vaccine uptake, current policy on vaccination

567 campaigns and routine immunization may need to be reviewed to address the barriers to YF vaccination  
568 identified in this study. The COVID-19 pandemic, the rainy season, being 15 years or older, residing in  
569 the northern region, and certain occupation have been shown to be impediment to YF vaccination. Our  
570 findings are critical for planning public health interventions and to guide research strategies that would  
571 enable Nigeria to meet the 2026 target of the WHO EYE strategy.

572

## 573 **Supporting information**

574 **S1 Fig: Map of Nigeria.** (a) geo-political zones (b) ecological  
575 zones

576 **S1 Table. Comparison of seasonal, geographical, and socio-**  
577 **demographic characteristics among reported Yellow fever**  
578 **cases in Nigeria, 2017-2021 by vaccination status.**

## 579 **Acknowledgement**

580 We sincerely appreciate the Program for Nurturing Global Leaders in Tropical and Emerging  
581 Communicable Diseases, Graduate School of Biomedical Sciences, Nagasaki University, the  
582 Management of the Nigeria Centre for Disease Control, and Japan International Cooperation  
583 Agency.

## 584 **Author contributions**

585 **Conceptualization:** Stephen E. Akar, Kaneko Satoshi

586 **Data curation:** Stephen E. Akar, Akanimo Iniobong, William Nwachukwu, Chinwe Ochu,

587 Olajumoke Babatunde, Ifedayo Adetifa, Chikwe Ihekweazu

588 **Data analysis:** Stephen E. Akar, Kaneko Satoshi

589 **Methodology:** Stephen E. Akar, Mami Hitachi, Kentaro Kato, Kaneko Satoshi

590 **Supervision:** Satoshi Kaneko, Yuki Takamatsu, Kenji Hirayama

591 **Validation:** Satoshi Kaneko, Kentaro Kato, Mami Hitachi, Stephen E. Akar

592 **Writing original (original draft):** Stephen E. Akar, Satoshi Kaneko

593 Writing (review and editing): Stephen E. Akar, William Nwachukwu, Akanimo Iniobong,

594 Oyeladun Okunromade, Chinwe Ochu, Olajumoke Babatunde, Ifedayo Adetifa, Chikwe

595 Ihekweazu, Mami Hitachi, Kentaro Kato, Yuki Takamatsu, Kenji Hirayama, Satoshi Kaneko

## 596 **Funding**

597 SEA received funding in the form of PhD fellowship scholarship from the Japan International

598 Cooperation Agency (<https://www.jica.go.jp/english/>) for implementation of this research work.

599 The funders had no role in study design, data collection and analysis, decision to publish, or

600 preparation of the manuscript.

## 601 **Data Availability Statement**

602 The dataset used in our study is a third-party data archived with the NCDC, which is the national

603 public health institute in Nigeria. Access is granted by the NCDC on request for specific dataset.

604 Such request could be directed to [dgo@ncdc.gov.ng](mailto:dgo@ncdc.gov.ng).

## 605 **References**



- 606 1. Tomori O. Impact of yellow fever on the developing world. *Adv Virus Res.* 1999;53: 5–34.  
607 doi:10.1016/s0065-3527(08)60341-3
- 608 2. Escosteguy CC, Pereira A, Marques M, de Araujo Lima T, Galliez R, de Andrade MR. Yellow fever:  
609 Profile of cases and factors associated with death in a hospital in the State of Rio de Janeiro,  
610 2017-2018. *Rev Saude Publica.* 2019;53: 89. doi:10.11606/S1518-8787.2019053001434
- 611 3. Rugarabamu S, Mwanyika GO, Rumisha SF, Sindato C, Lim HY, Misinzo G, et al. Seroprevalence  
612 and associated risk factors of selected zoonotic viral hemorrhagic fevers in Tanzania. *Int J Infect*  
613 *Dis.* 2021;109: 174–181. doi:10.1016/J.IJID.2021.07.006
- 614 4. Asebe G, Michlmayr D, Mamo G, Abegaz WE, Endale A, Medhin G, et al. Seroprevalence of Yellow  
615 fever, Chikungunya, and Zika virus at a community level in the Gambella Region, South West  
616 Ethiopia. *PLoS One.* 2021;16: e0253953. doi:10.1371/JOURNAL.PONE.0253953
- 617 5. Nomhwange T, Jean Baptiste AE, Ezebilo O, Oteri J, Olajide L, Emelife K, et al. The resurgence of  
618 yellow fever outbreaks in Nigeria: a 2-year review 2017–2019. *BMC Infect Dis.* 2021;21: 1–12.  
619 doi:10.1186/S12879-021-06727-Y/TABLES/2
- 620 6. Adogo LY, Ogoh MO. Yellow fever in Nigeria: A review of the current situation. *Afr J Clin Exper*  
621 *Microbiol.* 2019;21: 1–13. doi:10.4314/ajcem.v21i1.1
- 622 7. Tsegaye MM, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of yellow fever  
623 and related Flavi viruses in Ethiopia: A public health perspective. *BMC Public Health.* 2018;18:  
624 1011. doi:10.1186/s12889-018-5726-9
- 625 8. Abdullahi IN, Anka AU, Emeribe AU, Umar K, Adekola HA, Uzairue L, et al. The interplay between  
626 environmental factors, vector competence and vaccine immunodynamics as possible explanation  
627 of the 2019 yellow fever re-emergence in Nigeria. *New Microbes and New Infect.* 2021;41:  
628 100858. doi:10.1016/j.nmni.2021.100858
- 629 9. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new  
630 analyses. *Expert Rev Vaccines.* 2012;11: 427–448. doi:10.1586/ERV.12.6
- 631 10. Verma R, Khanna P, Chawla S. Yellow fever vaccine: An effective vaccine for travelers. *Hum*  
632 *Vaccin Immunother.* 2014;10: 126–128. doi:10.4161/HV.26549
- 633 11. Nwachukwu WE, Yusuff H, Nwangwu U, Okon A, Ogunniyi A, Imuetinyan-Clement J, et al. The  
634 response to re-emergence of yellow fever in Nigeria, 2017. *Int J Infect Dis.* 2020;92: 189–196.  
635 doi:10.1016/j.ijid.2019.12.034
- 636 12. Collins ND, Barrett ADT. Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still  
637 Controlling Outbreaks In Modern Day. *Curr Infect Dis Rep .* 2017;19: 14. doi:10.1007/S11908-017-  
638 0566-9
- 639 13. Bonaldo MC, Sequeira PC, Galler R. The yellow fever 17D virus as a platform for new live  
640 attenuated vaccines. *Hum Vaccin Immunother.* 2014;10: 1256–1265. doi:10.4161/HV.28117


- 641 14. Servadio JL, Muñoz-Zanzi C, Convertino M. Estimating case fatality risk of severe Yellow Fever  
642 cases: systematic literature review and meta-analysis. *BMC Infect Dis.* 2021;21: 819.  
643 doi:10.1186/s12879-021-06535-4
- 644 15. Wariri O, Edem B, Nkereuwem E, Nkereuwem OO, Umeh G, Clark E, et al. Tracking coverage,  
645 dropout and multidimensional equity gaps in immunisation systems in West Africa, 2000–2017.  
646 *BMJ Glob Health.* 2019;4: e001713. doi:10.1136/bmjgh-2019-001713
- 647 16. Blanco MZ, Ola JK, Faiyaz A, De Guzman A, De VC, Reyes L, et al. Risk of Yellow fever outbreak in a  
648 rural community: Assessment of knowledge, attitude and prevalence of risk factors in Nigeria.  
649 *International Journal of Infectious Diseases.* 2020;101: 265–272. doi:10.1016/j.ijid.2020.09.705
- 650 17. WHO. Eliminate yellow fever epidemics (EYE) strategy 2017-2026. [cited 5 Jul 2023]. Available:  
651 [https://www.who.int/initiatives/eye-](https://www.who.int/initiatives/eye-strategy#:~:text=The%20EYE%20strategy%20is%20a,contain%20outbreaks%20rapidly)  
652 [strategy#:~:text=The%20EYE%20strategy%20is%20a,contain%20outbreaks%20rapidly](https://www.who.int/initiatives/eye-strategy#:~:text=The%20EYE%20strategy%20is%20a,contain%20outbreaks%20rapidly).
- 653 18. Nigerian Centre for Disease. National Guidelines for Yellow Fever Preparedness and Response.  
654 Abuja; 2019. Report No.: 1. Available:  
655 [https://www.ncdc.gov.ng/themes/common/docs/protocols/118\\_1581155661.pdf](https://www.ncdc.gov.ng/themes/common/docs/protocols/118_1581155661.pdf)
- 656 19. Olajuyigbe S. Green gold of Africa: Nigeria’s forest, a depleted but resilient renewable resource.  
657 *Irish Forestry.* 2018;75: 92–111.
- 658 20. Federal Ministry of Environment. National Forest Reference Emission Level (FREL). Final report.  
659 Abuja. Department of Forestry, FMOE, Federal Republic of Nigeria; 2019 Jan. Report No.: 1.  
660 Available: [https://redd.unfccc.int/files/nigeria\\_national\\_frel\\_modified\\_revised\\_\\_for\\_posting.pdf](https://redd.unfccc.int/files/nigeria_national_frel_modified_revised__for_posting.pdf)
- 661 21. Olaleye OA, Ameh CE (Department of Forestry). Data Collection and Analysis for Sustainable  
662 Forest Management in ACP Countries - Linking National and International Efforts (Forest  
663 Resource Situation Assessment of Nigeria ). Final report. Abuja: EC-FAO Partnership Programme  
664 (1998-2002); 1999 Apr. Available: <https://www.fao.org/3/ab578e/ab578e.pdf>
- 665 22. Mengesha Tsegaye M, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of  
666 yellow fever and related Flavi viruses in Ethiopia: a public health perspective. *BMC Public Health.*  
667 2018;18: 1011. doi:10.1186/s12889-018-5726-9
- 668 23. Tuboi SH, Costa ZGA, da Costa Vasconcelos PF, Hatch D. Clinical and epidemiological  
669 characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. *Trans R Soc Trop  
670 Med Hyg.* 2007;101: 169–175. doi:10.1016/j.trstmh.2006.04.001
- 671 24. Venables WN, Riply BD. *Modern Applied Statistics with S.* 4th ed. Oxford: Springer; 2002.  
672 Available: <https://www.stats.ox.ac.uk/pub/MASS4/>
- 673 25. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the  
674 Tidyverse. *J Open Source Softw.* 2019;4: 1686. doi:10.21105/joss.01686
- 675 26. Kazuki Yoshida. Introduction to tableone. [cited 20 May 2023]. Available: [https://cran.r-](https://cran.r-project.org/web/packages/tableone/vignettes/introduction.html)  
676 [project.org/web/packages/tableone/vignettes/introduction.html](https://cran.r-project.org/web/packages/tableone/vignettes/introduction.html)

- 677 27. Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible Summary Tables with the  
678 gtsummary Package. *R J.* 2021;13: 570–580.
- 679 28. Rami Krispin. *Applied Time Series Analysis and Forecasting with R.* 1st ed. Online: Github; 2021.  
680 Available: <https://ramikrispin.github.io/atsaf/>
- 681 29. Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. *Trop  
682 Dis Travel Med Vaccines.* 2020;6: 1–10. doi:10.1186/s40794-020-0101-0
- 683 30. Hansen CA, Barrett ADT. The present and future of yellow fever vaccines. *Pharmaceuticals.*  
684 2021;14: 891. doi:10.3390/ph14090891
- 685 31. Clara A, Ndiaye SM, Joseph B, Nzogu MA, Coulibaly D, Alroy KA, et al. Community-Based  
686 Surveillance in Côte d’Ivoire. *Health Secur.* 2020;18: S23–S33. doi:10.1089/hs.2019.0062
- 687 32. Shioda K, Weinberger DM, Mori M. Navigating through Health Care Data Disrupted by the COVID-  
688 19 Pandemic. *JAMA Intern Med.* 2020;180: 1569–1570. doi:10.1001/jamainternmed.2020.5542
- 689 33. Bakare AA, Olojede OE, King C, Graham H, Uchendu O, Colbourn T, et al. Care seeking for under-  
690 five children and vaccine perceptions during the first two waves of the COVID-19 pandemic in  
691 Lagos State, Nigeria: a qualitative exploratory study. *BMJ Open.* 2023;13: e069294.  
692 doi:10.1136/BMJOPEN-2022-069294
- 693 34. Silva TMR, Nogueira de Sá ACMG, Prates EJS, Rodrigues DE, Silva TPR, Matozinhos FP, et al.  
694 Yellow fever vaccination before and during the covid-19 pandemic in Brazil. *Rev Saude Publica.*  
695 2022;56: 45. doi:10.11606/s1518-8787.2022056004503
- 696 35. Kwagonza L, Masiira B, Kyobe-Bosa H, Kadobera D, Atuheire EB, Lubwama B, et al. Outbreak of  
697 yellow fever in central and southwestern Uganda, February-may 2016. *BMC Infect Dis.* 2018;18:  
698 548. doi:10.1186/S12879-018-3440-Y
- 699 36. Abreu FVS de, de Andreazzi CS, Neves MSAS, Meneguete PS, Ribeiro MS, Dias CMG, et al.  
700 Ecological and environmental factors affecting transmission of sylvatic yellow fever in the 2017–  
701 2019 outbreak in the Atlantic Forest, Brazil. *Parasit Vectors.* 2022;15: 23. doi:10.1186/s13071-  
702 021-05143-0
- 703 37. Ribeiro AF, Cavalin RF, Suleiman JMAH, Da Costa JA, De Vasconcelos MJ, Málaque CMSA, et al.  
704 Yellow fever: Factors associated with death in a hospital of reference in infectious diseases, São  
705 Paulo, Brazil, 2018. *American Journal of Tropical Medicine and Hygiene.* 2019;101: 180–188.  
706 doi:10.4269/ajtmh.18-0882
- 707 38. Faria NR, Kraemer MUG, Hill SC, De Jesus JG, Aguiar RS, Iani FCM, et al. Genomic and  
708 epidemiological monitoring of yellow fever virus transmission potential. *Science (1979).*  
709 2018;361: 894–899. doi:10.1126/SCIENCE.AAT7115
- 710 39. Kallas EG, D’Elia Zanella LGFAB, Moreira CH V., Buccheri R, Diniz GBF, Castiñeiras ACP, et al.  
711 Predictors of mortality in patients with yellow fever: an observational cohort study. *Lancet Infect  
712 Dis.* 2019;19: 750–758. doi:10.1016/S1473-3099(19)30125-2


- 713 40. Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, et al. Recent immunization against  
714 measles does not interfere with the sero-response to yellow fever vaccine. *Vaccine*. 1999;17:  
715 1042–1046. doi:10.1016/S0264-410X(98)00320-X
- 716 41. Sorensen T, Sabroe S, Olsen J. A Framework for Evaluation of Secondary Data Sources for  
717 Epidemiological Research. *Int J Epidemiol*. 1996;25: 435–442. Available:  
718 <https://academic.oup.com/ije/article/25/2/435/688378>
- 719




(A) All cases




(B) Vaccinated cases




(C) Unvaccinated cases



(D) Unknown status



Figure




Figure

## (A) Negative cases

Epidemic.period	Before pandemic	-
	During pandemic	1.40 (1.14-1.72, p=0.002)
Age.group	0-4	-
	5-9	0.89 (0.65-1.23, p=0.488)
	10-14	1.13 (0.79-1.61, p=0.515)
	15-29	1.81 (1.28-2.57, p=0.001)
	30-44	1.78 (1.18-2.68, p=0.005)
	45-59	1.66 (0.95-2.92, p=0.076)
Geographical.region	South	-
	North	4.39 (3.58-5.40, p<0.001)
Occupation	Home-based/office	-
	Unemployed	0.95 (0.68-1.33, p=0.767)
	Student	0.83 (0.62-1.10, p=0.200)
	Butcher/farmer/hunter	1.63 (1.08-2.47, p=0.021)
	Artisan/trader	0.92 (0.55-1.53, p=0.736)
	Health worker	4.03 (1.33-17.47, p=0.028)


medRxiv preprint doi: <https://doi.org/10.1101/2023.09.20.23295820>; this version posted September 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




## (B) Unconfirmed cases

Climatic.season	Dry season	-
	Rainy season	1.28 (0.94-1.75, p=0.115)
Age.group	0-4	-
	5-9	1.01 (0.62-1.63, p=0.969)
	10-14	2.01 (1.15-3.54, p=0.015)
	15-29	2.85 (1.81-4.52, p<0.001)
	30-44	2.56 (1.49-4.44, p=0.001)
	54-59	4.17 (2.01-9.06, p<0.001)
	60+	10.76 (2.58-74.36, p=0.004)
Geographical.region	South	-
	North	3.05 (2.24-4.18, p<0.001)
Educational.status	Education	-
	No education	1.31 (0.92-1.86, p=0.136)
Occupation	Home-based/office	-
	Unemployed	-
	Student	0.58 (0.38-0.88, p=0.010)
	Butcher/farmer/hunter	1.28 (0.67-2.40, p=0.449)
	Artisan/trader	1.10 (0.52-2.32, p=0.799)
	Health worker	0.40 (0.09-1.81, p=0.218)
Occupational.setting	Indoor	-
	Outdoor	0.66 (0.35-1.26, p=0.207)







(A) Time trend by laboratory test status



(B) Time trend by vaccination status



Figure




Figure

## (A) Unvaccinated cases


Sex	Female	-
	Male	6.35 (1.66-32.16, p=0.012)
Geographical.region	North	-
	South	76.64 (13.57-1465.89, p<0.001)
Occupational.setting	Indoor	-
	Outdoor	3.11 (0.91-12.03, p=0.079)
Fatigue	No	-
	Yes	3.87 (1.10-15.08, p=0.039)
Hemorrhagic.symptoms	No	-
	Yes	368.00 (14.29-14759.72, p<0.001)
Vomiting	No	-
	Yes	6.53 (1.57-27.23, p=0.009)

medRxiv preprint doi: <https://doi.org/10.1101/2023.09.20.23295820>; this version posted September 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




## (B) Unknown vaccination status


Annual.quarter	Second quarter	-
	First quarter	0.98 (0.28-3.45, p=0.972)
	Third quarter	4.44 (1.92-12.11, p=0.001)
	Fourth quarter	3.38 (1.08-10.90, p=0.035)
Climatic.season	Dry season	-
	Rainy season	0.21 (0.08-0.44, p<0.001)
Age.group	<15 years	-
	>=15 years	1.87 (1.17-3.10, p=0.012)
Eco.zone	Sahel/Sudan savannah	-
	Derived savannah	7.09 (3.35-17.45, p<0.001)
	Lowland/Freshwater rainforest	1.26 (0.53-3.36, p=0.614)
	Guinea savannah/Jos Plateau	5.24 (2.41-13.14, p<0.001)
Fatigue	No	-
	Yes	1.25 (0.78-1.96, p=0.338)
Vomiting	No	-
	Yes	1.35 (0.75-2.37, p=0.301)
Hemorrhagic.symptoms	No	-
	Yes	2.94 (0.59-11.81, p=0.147)



(A) All suspected cases



(B) YFV positive cases



Figure